Medtronic Increases 2027 Forecasts Amid Heart Device Surge

Medtronic has raised its fiscal 2027 financial outlook, driven by robust demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, up from the previously projected 6.75% to 7.25%. CEO Geoff Martha highlighted the broad performance across Medtronic's businesses and contributions from newer growth platforms as key factors behind the optimistic forecast.

Strategic Investments in Heart Technology

In line with its growth strategy, Medtronic announced an $80 million investment in Pi-Cardia, a maker of heart-valve repair devices, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the U.S. Martha noted that the integration of Cornerstone's Sentire device complements Medtronic's existing Hugo platform, particularly in emerging markets where soft tissue robotic surgery penetration remains under 1%.

Financial Performance and Market Dynamics

Medtronic's cardiovascular segment reported a significant 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely fueled by an 88% surge in its pulsed field ablation portfolio, which is utilized to treat irregular heart rhythms. For the quarter, the company posted an adjusted per-share profit of $1.45 on revenues of $9.76 billion, surpassing LSEG-compiled estimates of $1.39 per share on $9.55 billion in sales.

Despite receiving tariff refunds that nearly covered the duties paid during the quarter, Medtronic's finance chief Thierry Pieton stated that future refunds have not been factored into the company's outlook. The strategic focus remains on high-growth medtech segments with large patient pools, as emphasized by Martha during a post-earnings call.